To include your compound in the COVID-19 Resource Center, submit it here.

GDC-0941: Interim Phase Ib data

Interim data from 27 patients in an ongoing, open-label, dose-escalation, U.S. Phase Ib trial showed that once-daily

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE